Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4452W HIGH $2.14
Volume
15.75 M
Value Traded
29.50 K
Short % Float
4.35%
+15.6%Week
-17%1 Month
-16.83%3 Month
-29.95%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.51 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
2.19 M
Total Shares
6.08 M
Float Shares
5.41 M
Insiders
11.09%
Institutions
5.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RDHL Catalyst Timeline
Dated clinical, regulatory and corporate events for Redhill Biopharma Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Redhill Biopharma Ltd.
1721Total events
7Upcoming
428Tier-1 (high impact)
2012 to 2042Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
RedHill reported operational highlights and financial results for the six months ended June 30, 2026
◆Other Regulator MilestoneOpaganibFiledEx-US Regulatory
Partnership discussions ongoing with African Medicines Agency, Ugandan Ministry of Health, MUST, and DRC Scientific Advisory Committee for opaganib Ebola development
Ebola virus diseasesource ↗
▲Preclinical PoCOpaganibFiledPreclinical
USAMRIID-funded preclinical studies showed opaganib inhibition of EVD in human macrophages, increased survival, and synergy with remdesivir
Ebola virus diseasesource ↗
●Quarterly UpdateOpaganibFiledCorporate
Ebola outbreak update: 3221 cases and 1407 deaths reported
Ebola virus diseasesource ↗
▼Equity OfferingCorporate
Closing of private placement raising $6 million upfront with potential additional $13.4 million from warrant exercise
▲Rare Pediatric DiseaseOpaganibFiledDesignation
FDA granted rare pediatric disease designation to opaganib for neuroblastoma
neuroblastomasource ↗
◆Partnership / LicenseOpaganibFiledCorporate
Actively discussing potential collaborations for opaganib in EVD, including WHO SOLIDARITY CORE platform
Ebola virus diseasesource ↗
◆Partnership / LicenseOpaganibFiledCorporate
Active discussions for potential collaborations including WHO SOLIDARITY CORE platform
Ebola virus diseasesource ↗
▲Preclinical PoCRHB-204Preclinical
RHB-204 demonstrates comparable MAP killing efficacy to RHB-104 in in vitro assays
Crohn's diseasesource ↗
▲Poster PresentationOpaganibFiledPresentation
Poster presentation at AACR 2026: Opaganib potentiates STING activation in TNBC in vitro
triple-negative breast cancersource ↗
▲Product LaunchTALICIA®ApprovedPost-Market
Full sales and operational launch of Talicia under joint commercialization agreement with Cumberland
H. pylori infectionsource ↗
▲Product LaunchTALICIA®ApprovedPost-Market
Full sales and operational launch of Talicia by THI
H. pylori infectionsource ↗
▲Poster PresentationOpaganibFiledPresentation
Preclinical data presented at AACR 2026 showing positive effects in neuroblastoma and TNBC models
neuroblastoma and triple-negative breast cancersource ↗
▲Rare Pediatric DiseaseOpaganibFiledDesignation
FDA granted Rare Pediatric Disease Designation to opaganib for neuroblastoma
neuroblastomasource ↗
▲Preclinical PoCOpaganibFiledPreclinical
New preclinical data for opaganib as add-on therapy in neuroblastoma and TNBC presented at AACR
neuroblastoma and triple-negative breast cancersource ↗
▲Preclinical PoCRHB-204Preclinical
New RHB-204 in vitro data demonstrated comparable MAP killing to RHB-104
Crohn's diseasesource ↗
▲Partnership / LicenseCorporate
RedHill acquired exclusive global and U.S. commercialization rights to Rebyota and Clenpiq for $12 million upfront plus milestones and royalties
▲Preclinical PoCOpaganibFiledPreclinical
Positive in vivo results: opaganib + venetoclax reduces CLL cells by 50% vs controls
Chronic Lymphocytic Leukemia (CLL)source ↗
▲IP Litigation RulingIP / Competition
New York Supreme Court $10.5M summary judgment in favor of RedHill against Kukbo final and eligible for enforcement
▲Partnership / LicenseTALICIA®ApprovedCorporate
Strategic partnership with Cumberland Pharmaceuticals for U.S. co-commercialization of Talicia
H. pylori infectionsource ↗
▼Equity OfferingCorporate
Cumberland invests $4 million in RedHill for 30% stake in Talicia business
▲Partnership / LicenseTALICIA®ApprovedCorporate
Licensing of Talicia for new Middle East markets
H. pylori infectionsource ↗
▲Partnership / LicenseTALICIA®ApprovedCorporate
Joint commercialization agreement between Talicia Holdings Inc. and Cumberland Pharmaceuticals
H. pylori infectionsource ↗
▼Equity OfferingCorporate
Cumberland's $4 million strategic investment in Talicia Holdings Inc.
▲Other Regulator MilestoneTALICIA®ApprovedEx-US Regulatory
Licensing of Talicia for new Middle East markets
H. pylori infectionsource ↗
◆MHRA MilestoneTALICIA®ApprovedEx-US Regulatory
Potential UK approval for Talicia
Helicobacter pylori infectionsource ↗
▲Codev CocommercialTALICIA®ApprovedCorporate
U.S. co-commercialization partnership with Cumberland Pharmaceuticals for Talicia
H. pylori infectionsource ↗
▲Partnership / LicenseCorporate
RedHill divested its 70% stake in Talicia for $18 million upfront plus up to $35 million in potential milestone payments
▲Trial InitiationOpaganibFiledTrial
Phase 2 study of opaganib and darolutamide started recruiting patients
prostate cancersource ↗
▲IND ClearanceRHB-204IND
FDA green light for planned Crohn's program with RHB-204
Crohn's diseasesource ↗
▲Partnership / LicenseRHB-102Corporate
Up to $60 million RHB-102 out-licensing deal to Hyloris Pharma
chemotherapy and radiotherapy induced nausea and vomitingsource ↗
▲Enrollment MilestoneTALICIA®ApprovedTrial
Talicia secured 8 million additional covered lives from formulary wins
H. pylori infectionsource ↗
▲Enrollment CompleteTALICIA®ApprovedTrial
Talicia surpassed 100,000 prescriptions milestone
H. pylori infectionsource ↗
▲Milestone PaymentTALICIA®ApprovedCorporate
First ex-U.S. sales milestone payment and royalties received
Helicobacter pylori infectionsource ↗
▲Type C MeetingFDA Meeting
FDA Type C meeting with positive feedback on RHB-204 pathway to approval
▲FDA Feedback ReceivedRHB-204FDA Meeting
Positive FDA feedback on RHB-204 Phase 2 study design and endpoints
Crohn's diseasesource ↗
▲First Patient DosedOpaganibFiledTrial
Recruitment initiated into Phase 2 opaganib/darolutamide combination study in advanced prostate cancer
metastatic castrate-resistant prostate cancersource ↗
◆ATM ProgramCorporate
Entered into ATM agreement with Alumni Capital LP for up to $10 million
◆Oral PresentationTALICIA®ApprovedPresentation
Medscape CME Part 2: Expert Roundtable: Overcoming Challenges in H. pylori Diagnosis and Treatment
H. pylori infectionsource ↗
▼Equity OfferingCorporate
Any Market Purchase Agreement with Alumni Capital LP for up to $10M ADSs
◆Type C MeetingRHB-204FDA Meeting
Type C meeting with FDA for RHB-204 in Crohn's disease
Crohn's diseasesource ↗
◆FDA Feedback ReceivedRHB-204FDA Meeting
FDA guidance from Type C meeting for RHB-204
Crohn's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How RDHL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2020-12-31 | Opaganib (ABC294640, Yeliva) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$4M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.4x
rNPV / MCap
Top 40%
Micro Cap(rank 264 of 658)
Percentile Rank
Redhill Biopharma Ltd. carries a moderate pipeline score (40/100), with $1.7B risk-adjusted pipeline value, led by RHB-104 in Relapsing Remitting Multiple Sclerosis (Phase 2), across $69B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RHB-104 Small moleculeCompletedNCT03009396 | Crohn Disease | Phase 3 | COMPLETED | 385 | Aug 19, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every RDHL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RHB-104 | Crohn's disease | Phase 3 | 2026-04-30 | 64% more effective than SoC alone, p = 0.0048Read More | RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Raday GileadOfficer (Chief Operating Officer) | Sell | -14,310,000 176,910,000 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RDHL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.7 % (-12.5 %) | 3.14 M | 455.93 K |
RDHL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RDHL ranks across every disease it competes in
Competitive Position is a premium feature
See how RDHL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRDHL News
RDHLRedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
RedHill Biopharma reported operational highlights and financial results for the first half of 2026, showcasing a strategic portfolio reset. The company successfully acquired commercialization rights to FDA-approved drugs Rebyota and Clenpiq, enhancing its revenue potential. Despite a net loss of $6.1 million, RedHill is optimistic about its R&D pipeline, particularly in oncology and gastrointestinal diseases.
Read more →RDHLRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
RedHill Biopharma has announced a significant acquisition of the commercialization rights to Ferring's Rebyota® and Clenpiq®. This strategic move is expected to bolster RedHill's product offerings and potentially increase its market presence. The acquisition reflects RedHill's commitment to expanding its portfolio in the biopharmaceutical sector.
Read more →RDHLRedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
RedHill Biopharma has divested its Talicia® product to Apotex for $18 million in cash, along with additional milestone payments. This strategic decision aims to enhance RedHill's focus on growth opportunities. The transaction is expected to provide immediate financial benefits and support the company's future initiatives.
Read more →RDHLEbola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
RedHill Biopharma has reported a significant increase in Ebola cases and deaths, now totaling 3,221 cases and 1,407 deaths. The company is advancing the development of opaganib as a potential treatment for Bundibugyo ebolavirus, supported by promising clinical data. Discussions with health authorities are ongoing to facilitate the drug's evaluation and potential use in the current outbreak.
Read more →RDHL▲ +10.2%on this news
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma has successfully closed a private placement, raising $6 million upfront with the potential for an additional $13.4 million through warrants. The funds are aimed at enhancing the company's liquidity and supporting potential acquisitions of revenue-generating pharmaceutical assets. However, no definitive acquisition agreement is in place, and the transaction is subject to various conditions.
Read more →RDHLRedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill Biopharma has announced a definitive agreement for a private placement of American Depositary Shares (ADSs) expected to raise up to $19.4 million. The initial $6 million will be supplemented by potential proceeds from warrants. The funds are intended for strategic acquisitions and general corporate purposes, but there are no guarantees regarding the exercise of warrants or completion of acquisitions.
Read more →RDHL▼ -21.6%on this news
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of ...
RedHill Biopharma announced that the FDA has granted its drug opaganib a rare pediatric disease designation for treating neuroblastoma, a cancer primarily affecting infants and young children. This designation complements its existing orphan drug status, offering potential advantages like accelerated review processes and marketing exclusivity if approved. Newly presented preclinical data indicate opaganib's positive effects as a potential add-on therapy in neuroblastoma treatment. The global market for neuroblastoma is expected to reach approximately $3.5 billion by 2032.
Read more →RDHLRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Biopharma has initiated enforcement proceedings in Korea following a New York Supreme Court judgment awarding approximately $10.9 million against Kukbo Co. Ltd. This includes a principal amount and legal fees. The company awaits Kukbo's response while recognizing that recovery timing and amounts remain uncertain.
Read more →RDHLRedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
RedHill Biopharma is actively pursuing collaborations to advance the clinical application of opaganib to combat Ebola Virus Disease, particularly amid an outbreak of the Bundibugyo ebolavirus subtype. Recent data suggests that opaganib could significantly reduce mortality rates and improve viral clearance times based on its performance in severe COVID-19 treatment. Although promising, opaganib remains an investigational product that has yet to receive regulatory approval, and its inclusion in key clinical trial platforms like WHO's SOLIDARITY CORE is not assured.
Read more →RDHLRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma is exploring collaborations to advance opaganib for treating the current Ebola outbreak caused by the Bundibugyo ebolavirus subtype. The company is discussing its investigational oral drug's potential with the WHO's SOLIDARITY CORE clinical trial platform. Opaganib has shown promising antiviral properties and a favorable safety profile, making it a candidate for addressing this public health threat.
Read more →RDHLRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill Biopharma's RHB-204 has demonstrated comparable efficacy in killing Mycobacterium avium subspecies paratuberculosis (MAP) to RHB-104 in recent studies. This next-generation formulation aims to enhance tolerability and safety for Crohn's disease patients. The upcoming Phase 2 study is set to be the first controlled clinical trial in a MAP-positive patient population, potentially revolutionizing treatment approaches.
Read more →RDHLRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma reported its 2025 financial results, highlighting strategic transactions including the establishment of Talicia Holdings Inc. and a partnership with Cumberland Pharmaceuticals. Despite facing operating losses of $7.9 million, the company noted a significant turnaround in net income from discontinued operations resulting from a gain on the loss of control over Talicia. The R&D pipeline is progressing, especially with RHB-204 for Crohn's disease and opaganib in oncology. Overall, RedHill indicated a sound position for future growth and market expansion.
Read more →RDHL▲ +5.8%on this news· ran to +29% by day 1shared move
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show...
New preclinical data presented at the 2026 AACR Annual Meeting highlights the potential of opaganib, a drug developed by RedHill Biopharma, as an add-on therapy for neuroblastoma and triple-negative breast cancer. Studies indicate that opaganib enhances the efficacy of existing chemotherapy treatments by destabilizing the oncogenic driver n-Myc in neuroblastoma and augmenting anti-tumor immunity in triple-negative breast cancer. The findings from this research may support further clinical development of opaganib in oncology indications, especially considering its FDA Orphan Drug designation for neuroblastoma.
Read more →RDHLJoint U.S. Commercialization of RedHill's Talicia® Commences
RedHill Biopharma and Cumberland Pharmaceuticals have commenced the full sales and operational launch of Talicia, an FDA-approved treatment for H. pylori infection. This joint commercialization aims to enhance market penetration and patient access to Talicia, which is recognized as the leading therapy for H. pylori. The collaboration is expected to leverage combined expertise for improved prescription growth and operational efficiencies.
Read more →RDHL▲ +35.9%on this news
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RedHill Biopharma announced progress in the development of RHB-102, a once-daily oral ondansetron formulation aimed at treating gastrointestinal side effects associated with GLP-1 receptor agonist therapies. The drug has shown positive results in Phase 2 and Phase 3 studies for various indications, including IBS-D and gastroenteritis. RedHill plans to pursue FDA approval through the accelerated 505(b)(2) pathway.
Read more →RDHLRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
RedHill Biopharma announced positive results from a study showing that opaganib, a sphingosine kinase 2 inhibitor, combined with venetoclax, reduces chronic lymphocytic leukemia (CLL) cell counts by 50%. This finding highlights opaganib's potential as an effective add-on therapy for patients resistant to venetoclax. The results are based on in vivo studies and support ongoing clinical evaluations.
Read more →RDHLRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Biopharma announced that it has regained compliance with Nasdaq's stockholders' equity requirement as of November 26, 2025. This achievement is part of the company's strategic initiatives, including a partnership with Cumberland Pharmaceuticals for the promotion of Talicia. The company continues to focus on operational efficiency and development of its drug pipeline.
Read more →RDHL▼ -13.6%on this news
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RedHill Biopharma announced that the New York Supreme Court's judgment in its favor against Kukbo Co. Ltd is now final, allowing for enforcement. The court awarded RedHill over $10.5 million, including approximately $8.6 million in the main judgment and $1.9 million for legal fees. Additionally, RedHill has secured a Korean court attachment to prevent Kukbo from disposing of assets.
Read more →RDHLRedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
RedHill Biopharma has secured a $4 million strategic investment from Cumberland Pharmaceuticals, acquiring a 30% stake in RedHill's Talicia business. This partnership aims to enhance Talicia's market presence and sales through shared operational responsibilities and marketing support. Talicia is recognized as a leading therapy for H. pylori infections and is protected by patents until 2042.
Read more →RDHLRedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
RedHill Biopharma has signed a licensing agreement worth $1.8 million for its drug Talicia in the Middle East. The deal includes guaranteed payments and potential milestone payments, alongside tiered royalties based on net sales. Talicia is recognized for its effectiveness against H. pylori, a major risk factor for gastric cancer, and is the only FDA-approved therapy of its kind. This agreement aims to enhance patient access to Talicia in a region with a high prevalence of H. pylori infections.
Read more →About Redhill Biopharma Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next RDHL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime